Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. [electronic resource]
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Nov 2014
- A387 p. digital